ArticlePharmaceuticals (Basel, Switzerland)2024
Safety and Efficacy of Selective Internal Radionuclide Therapy with
Alexander Bellendorf, Nicolai Mader, Stefan P Mueller, Samer Ezziddin, Andreas Bockisch, Hong Grafe, Jan Best, Juliane Goebel, Thorsten D Pöppel, Amir Sabet
Open access · goldAbstract read
In one paragraphArticle in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors at 4 institutions in 1 country.
Alexander BellendorfDepartment of Nuclear Medicine, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany.
Nicolai MaderDepartment of Nuclear Medicine, Clinic for Radiology and Nuclear Medicine, University Hospital, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany.ORCID 0000-0002-1636-9959 Stefan P MuellerDepartment of Nuclear Medicine, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany.
Samer EzziddinDepartment of Nuclear Medicine, Saarland University Medical Center, Kirrberger Straße, 66421 Homburg, Germany.ORCID 0000-0003-4110-3375 Andreas BockischDepartment of Nuclear Medicine, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany.
Hong GrafeDepartment of Nuclear Medicine, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany.
Jan BestDepartment of Internal Medicine, University Hospital Ruhr-University Bochum, In der Schornau 23-25, 44892 Bochum, Germany.
Juliane GoebelDepartment of Diagnostic and Interventional Radiology and Neuroradiology, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany.
Thorsten D PöppelDepartment of Nuclear Medicine, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany.
Amir SabetDepartment of Nuclear Medicine, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany.ORCID 0000-0003-3027-5083 University of Duisburg-Essen · DEGoethe University Frankfurt · DESaarland University · DEUniversity Hospitals of the Ruhr-University of Bochum · DE
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Transarterial chemoembolization (TACE) is currently the standard of care in patients with unresectable hepatocellular carcinoma (HCC), and selective internal radionuclide therapy (SIRT) with
Indexed as
90Y glass microsphereshepatocellular carcinoma (HCC)selective internal radionuclide therapy (SIRT)transarterial chemoembolization (TACE)
Identifiers
PMID38256934
PMCPMC10819448
OpenAlexW4390750807
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390